Researchers reported a fragmentomics approach designed to detect tumor-linked nucleosomal patterns by analyzing size distributions of circulating cell-free DNA. The technique connects fragment length with nucleosomal origins to identify tumor-associated fragmentomic alterations with high precision. The work is positioned as a shift in cancer diagnostics that could complement or enhance liquid biopsy workflows by adding a new layer of fragment-size biology rather than relying solely on mutation counting. While the provided excerpt does not include validation cohorts or clinical performance numbers, the core development is the ability to derive tumor-linked information from fragmentomic signatures.